Pharmaceutical

MSD ventures into fibroblast therapies with $1.9bn deal with Mestag

The deal allows MSD to license one or more therapies against inflammatory diseases developed using the UK biotech’s fibroblast platform.

Oct 10, 2024 - 04:00
MSD ventures into fibroblast therapies with $1.9bn deal with Mestag
The deal allows MSD to license one or more therapies against inflammatory diseases developed using the UK biotech’s fibroblast platform.
Read the original article

Tags:

Previous Article

Anima Biotech’s machine learning programme ‘reveals new mRNA drug targets’

Next Article

Emergent to donate 20,000 Narcan doses to fight opioid overdoses, CEO says

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition

Lilly bolsters IBD portfolio with $3.2bn Morphic acquis...

Jul 10, 2024

The potential of 3D printing in drug development and delivery

The potential of 3D printing in drug development and de...

Jul 26, 2024

Stock drama, cancer vaccine success, and new science — highlights from AACR

Stock drama, cancer vaccine success, and new science — ...

Apr 21, 2023